EirGenix Inc., a biopharmaceutical company based in Taiwan, known for its Contract Development and Manufacturing Organization (CDMO) services and independent biosimilar pipeline development, recently sealed a significant global exclusive licensing pact with Sandoz AG, a prominent player in the biosimilar market. This agreement focuses on the commercialization of EirGenix’s breast cancer biosimilar, EG1206A, a Pertuzumab biosimilar designed to mimic Roche’s Perjeta. The deal excludes specific territories, such as Taiwan, Mainland China, and Japan, while fortifying the partnership between the two companies in the development of HER2 biosimilar products.
In this lucrative agreement, EirGenix stands to gain up to USD 152 million in upfront and milestone payments. Additionally, the company will enjoy profit-sharing post-launch in the licensed regions and potential sales incentives based on market performance. EirGenix will spearhead the product’s development, manufacturing, and supply. Notably, EG1206A has successfully completed its pharmacokinetic (PK) clinical study and received positive feedback from the US FDA and the European Medicines Agency (EMA). This positive reception has enabled an expedited development pathway, bypassing phase III comparative efficacy trials.
The collaboration with Sandoz marks a significant milestone in EirGenix’s journey in biosimilar development. The company’s prior agreement with Sandoz for EG12014, a Trastuzumab biosimilar, has already seen approval from the European Commission and is currently undergoing review by the US FDA. The global prevalence of breast cancer, particularly HER2-positive cases, opens up a vast market for biosimilars like EG1206A. Combining Pertuzumab with Trastuzumab deruxtecan has shown promise as a potential first-line treatment for HER2-positive metastatic breast cancer, indicating a bright future for EG1206A in the market.
With the launch of EG1206A alongside the existing EG12014, EirGenix is poised to provide enhanced treatment options for HER2-positive breast cancer patients. The market potential is substantial, as evidenced by Roche’s annual report projecting global sales of Perjeta to reach USD 4 billion by 2024. Sandoz, known for its commitment to affordable medicines and patient access, is an ideal partner for EirGenix in bringing these biosimilars to a broader patient base.
EirGenix’s proficiency in reverse engineering technologies has been pivotal in developing multiple biosimilar products. This latest agreement not only highlights EirGenix’s global competitiveness and technical prowess but also underscores its ability to cater to international markets. With favorable regulatory trends in the biosimilar landscape, EirGenix is accelerating the development of four HER2-targeted antibody programs, expanding its product pipeline, and CDMO services for additional biosimilar ventures.
The increasing demand for biosimilar research and manufacturing presents a significant opportunity for EirGenix. The company’s technical expertise, production capacity, and state-of-the-art facilities have garnered attention from global pharmaceutical firms. The utilization of EirGenix’s production lines in Zhubei emphasizes the company’s rapid advancement. Positioned as a key player in the biosimilar market, EirGenix is set to solidify its position as a pivotal development and manufacturing partner on the global stage.
Key Takeaways:
- EirGenix’s licensing deal with Sandoz AG for EG1206A heralds a new chapter in biosimilar commercialization.
- The collaboration underscores the growing market for HER2-targeted biosimilars in breast cancer treatment.
- EirGenix’s technical excellence and internationalization capabilities position it as a key player in the global biosimilar landscape.
Tags: regulatory
Read more on pharmabiz.com